Dainippon Of Japan To Establish U.S. Holding Company
This article was originally published in PharmAsia News
Japan's Dainippon Sumitomo Pharma plans to establish a holding company in the United States to improve on the time it takes to get its drugs through the U.S. FDA approval process. The U.S. firm also is intended to serve as a sales base for its SM-13496 (lurasidone) drug for treating schizophrenia, which, although it is still in clinical trials, the company plans to have on the market as early as 2011. A Phase III trial of the drug has shown the drug to be far more effective than placebos in treating acute schizophrenia. (Click here for more - a subscription may be required
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.